Repeat Prescription
Monthly healthcare updates with Holly Gibson, Price Bailey's healthcare expert offering advice and insight on topical issues affecting the healthcare industry today.
With many life sciences breakthroughs and increasing demand for new technology from various sectors, the life sciences sector is full of exciting opportunities.
As specialists in supporting life science businesses, we know there are also challenges to overcome in commercialising innovations. You might need help raising finance for research or product development, or perhaps you’re looking for advice on financial compliance or commercial strategy.
Our specialist life sciences team offers a range of business services focused specifically on the needs of life sciences companies. These include:
We have supported many clients – including life sciences clients – through challenging times. However, looking forward, we are excited for what the future holds for companies and individuals situated within this industry.
The last couple of years has strengthened the reputation of the life sciences industry as being an inventive and adaptable industry due to the growth the industry experienced during the pandemic.
The question remains around how life science companies will sustain this high level of growth and continue to accelerate forward whilst their attention is focused on increasing revenue and profits, and sustaining their competitive advantage. Life sciences companies will also be determined by:
Contact us today to find out more about how we can help you
Monthly healthcare updates with Holly Gibson, Price Bailey's healthcare expert offering advice and insight on topical issues affecting the healthcare industry today.
Our first article in our supply chain series delves into the supply chain challenges faced by UK businesses in September 2024. Find out more...
Learn about the complexities of transfer pricing for financial transactions, including loans and treasury activities, and how to mitigate tax authority challenges.
Double cab pick-ups (DCPUs) are set to be reclassified for tax purposes, impacting capital allowances, benefits in kind (BIK), and certain business deductions. This change reverses an earlier decision and could lead to higher BIK liabilities...